Optimization of a Subcutaneous Epithelioid Hemangioendothelioma Xenograft Model for Evaluation of Preclinical Therapeutics

Low, sub-million cell inoculation in a patient-derived epithelioid hemangioendothelioma xenograft yields reproducible subcutaneous tumors with classical sigmoidal growth kinetics and an extended untreated control window.

• Why it matters: Epithelioid hemangioendothelioma has an unpredictable course and no standard-of-care, and the lack of clinically relevant preclinical models limits therapeutic development.
• What they did: The team optimized mouse subcutaneous xenografts using a patient-derived human EHE cell line, then confirmed EHE pathology by histology and marker expression (ERG, CAMTA1) and validated mTOR-pathway drug response.
• The result: Nab-sirolimus significantly suppressed tumor growth and reduced phosphorylation of ribosomal protein S6, supporting longitudinal evaluation of antitumor activity and mTORC1 pharmacodynamics in this model.

AI summary of the abstract · may contain errors · not medical advice · read the paper.